EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Therapeutic disruption of RAD52–ssDNA complexation via novel drug-like inhibitors

Divya S Bhat, Eva Malacaria, Ludovica Di Biagi, Mortezaali Razzaghi, Masayoshi Honda, Kathryn F Hobbs, Sarah R Hengel, Pietro Pichierri iD, M Ashley Spies, Maria Spies iD

NAR Cancer · 11.03.2023 · 5 (2)

DOI: 10.1093/narcan/zcad018 ↗

Kurz gefasst

Fachartikel in der Zeitschrift NAR Cancer, online erschienen am 01.05.2023. Verfasst von Divya S Bhat und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, University of Iowa Carver College of Medicine, 51 Newton Road, Iowa City, IA 52242, USA. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS, National Institutes of Health.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

RAD52 protein is a coveted target for anticancer drug discovery. Similar to poly-ADP-ribose polymerase (PARP) inhibitors, pharmacological inhibition of RAD52 is synthetically lethal with defects in genome caretakers BRCA1 and BRCA2 (∼25% of breast and ovarian cancers). Emerging structure activity relationships for RAD52 are complex, making it challenging to transform previously identified disruptors of the RAD52–ssDNA interaction into drug-like leads using traditional medicinal chemistry approaches. Using pharmacophoric informatics on the RAD52 complexation by epigallocatechin (EGC), and the Enamine in silico REAL database, we identified six distinct chemical scaffolds that occupy the same physical space on RAD52 as EGC. All six were RAD52 inhibitors (IC50 ∼23–1200 μM) with two of the compounds (Z56 and Z99) selectively killing BRCA-mutant cells and inhibiting cellular activities of RAD52 at micromolar inhibitor concentrations. While Z56 had no effect on the ssDNA-binding protein RPA and was toxic to BRCA-mutant cells only, Z99 inhibited both proteins and displayed toxicity towards BRCA-complemented cells. Optimization of the Z99 scaffold resulted in a set of more powerful and selective inhibitors (IC50 ∼1.3–8 μM), which were only toxic to BRCA-mutant cells. RAD52 complexation by Z56, Z99 and its more specific derivatives provide a roadmap for next generation of cancer therapeutics.

Autor:innen und Institutionen

  • Department of Biochemistry, University of Iowa Carver College of Medicine, 51 Newton Road, Iowa City, IA 52242, USA.
  • Mechanisms, Biomarkers and Models Section, Department of Environment and Health, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy.
  • Division of Medicinal and Natural Products Chemistry, Department of Pharmaceutical Sciences and Experimental Therapeutics, The University of Iowa, Iowa City, IA 52242, USA.
  • Naturis Informatika LLC, 401 Mullin Ave., Iowa City, IA 52246, USA.

ORCID-Profile: Pietro Pichierri, Maria Spies

Förderung

  • NCI NIH HHS
  • NIGMS NIH HHS
  • National Institutes of Health
  • University of Iowa Center for Biocatalysis and Bioprocessing
  • NIH-sponsored Predoctoral Training Program in Biotechnology
  • Free Radicals and Radiation Biology

Zitieren

APA

Bhat, D. S., Malacaria, E., Biagi, L. D., Razzaghi, M., Honda, M., Hobbs, K. F., Hengel, S. R., Pichierri, P., Spies, M. A., & Spies, M. (2023). Therapeutic disruption of RAD52–ssDNA complexation via novel drug-like inhibitors. NAR Cancer, 5(2). https://doi.org/10.1093/narcan/zcad018

Vancouver

Bhat DS, Malacaria E, Biagi LD, Razzaghi M, Honda M, Hobbs KF, et al. Therapeutic disruption of RAD52–ssDNA complexation via novel drug-like inhibitors. NAR Cancer. 2023;5(2). doi:10.1093/narcan/zcad018

BibTeX
@article{Bhat2023,
  author = {Bhat, Divya S and Malacaria, Eva and Biagi, Ludovica Di and Razzaghi, Mortezaali and Honda, Masayoshi and Hobbs, Kathryn F and Hengel, Sarah R and Pichierri, Pietro and Spies, M Ashley and Spies, Maria},
  title = {Therapeutic disruption of RAD52–ssDNA complexation via novel drug-like inhibitors},
  journal = {NAR Cancer},
  year = {2023},
  volume = {5},
  number = {2},
  doi = {10.1093/narcan/zcad018}
}
Kostenlos starten →